about header
News
Print Text Size

Featured Press Releases

  • December 3, 2014
    Genzyme, a Sanofi company, today announced that the first U.S. patients have initiated treatment with Lemtrada® (alemtuzumab) in the commercial setting following its November 14th FDA approval for the treatment of patients with relapsing forms of multiple sclerosis...
  • November 21, 2014
    Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Cerdelga® (eliglustat) capsules, an oral treatment for certain adults...
  • November 18, 2014
    Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that new two-year data from a phase 3 long-term extension study of KYNAMRO® (mipomersen sodium) injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the...
  • November 14, 2014
    Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should...

Please visit Genzyme's YouTube Channel to view all videos.

Leadership

David Meeker, M.D.
President; Chief Executive Officer

David Meeker, 57, was appointed CEO of Genzyme in October 2011. In his career with Genzyme, he has held key positions of increasing responsibility, most recently as Chief Operating Officer. More...

Contact Us
 

Media Resources

Tweets

Social Media

 

Business Wire NewsHQ℠
infoBox